We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

By LabMedica International staff writers
Posted on 09 Feb 2024

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers (CE sequencers). More...

This collaboration stems from the outcomes of joint research conducted since the signing of a feasibility study (FS) agreement in August 2023, which focused on creating new genetic testing systems. The goal of Sysmex and Hitachi High-Tech is to produce genetic testing systems that are more efficient and cost-effective, thereby facilitating the widespread clinical application of personalized genetic testing for various diseases.

The field of genetic testing has seen significant advancements in assay reagent development using next-generation sequencing (NGS). However, there are challenges such as reducing measurement times and operational costs, underscoring the need for novel genetic testing systems suitable for widespread clinical use. To address these challenges, the companies signed the FS agreement in August 2023. The agreement aimed at exploring the development of new genetic testing systems that could offer optimal genetic analysis for individual diseases. This would be achieved by combining Hitachi High-Tech’s CE sequencer technology with Sysmex’s expertise in NGS reagent development and analysis technology, both honed through the advancement of genomic medicine in clinical settings.

Having met the objectives outlined in the FS agreement, Sysmex and Hitachi High-Tech have now agreed to proceed with the development of genetic testing systems intended for broad clinical use. Hitachi High-Tech will focus on obtaining medical device approvals for their CE sequencers, while Sysmex will develop and seek regulatory approvals for testing reagents compatible with these devices, as well as developing analysis software. Initially, the collaboration will concentrate on applications in oncology before gradually extending to other disease areas. By leveraging each company’s unique technologies and expertise, Sysmex and Hitachi High-Tech aim to promote the adoption of new genetic testing systems that offer shorter measurement durations and reduced operational costs.

Related Links:
Sysmex Corporation
Hitachi High-Tech Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Automatic CLIA Analyzer
Shine i6000
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.